NCT02771236 Clinical and Molecular Studies in Families With Inherited Eye Disease
| NCT ID | NCT02771236 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Eye Institute (NEI) |
| Condition | Inherited Eye Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,800 participants |
| Start Date | 2016-10-04 |
| Primary Completion | 2032-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,800 participants in total. It began in 2016-10-04 with a primary completion date of 2032-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Genes are the basic units of heredity. When genes are changed, certain cells don t work like they should. Researchers want to try to better understand the genetic conditions that are linked with inherited eye diseases. Objective: To try to identify the genes linked to the development of inherited eye diseases. Eligibility: People ages 4 and older who have or have a family member with an inherited eye disease Design: Participants will be screened with medical history and medical records. Participants will have one visit that will take 3-4 hours. This will include: Medical and family history Eye exam: This includes the pupil being dilated. Electroretinography: A small electrode is taped to the forehead. Participants sit in the dark with their eyes patched for 30 minutes. Then numbing drops and contact lenses are put in the eyes. They will watch flashing lights. Blood tests Saliva sample: They will spit into a container or have the inside of their cheek swabbed. Genetic testing will be done on participants blood or saliva. Participants may meet with the researchers to discuss their genetic tests. ...
Eligibility Criteria
* INCLUSION CRITERIA: To be eligible, the following inclusion criteria must be met, where applicable; 1. Participant must be four years of age or older. 2. Participant must understand and sign the protocol s informed consent document. 3. Individuals or family members of individuals with inherited eye diseases, either congenital, childhood, or age related. 4. All participants must be able to cooperate with study examination and phlebotomy. EXCLUSION CRITERIA: A participant is not eligible if any of the following exclusion criteria are present: 1. Participant has a disease, infection, or trauma that mimics inherited cataracts, retinal degenerations, glaucoma, etc. 2. Participant has a significant active infection (an infection requiring treatment as determined by the investigator) or a history of chronic or recurrent infections. 3. Participant requires sedation for study purposes.
Contact & Investigator
James F Hejtmancik, M.D.
PRINCIPAL INVESTIGATOR
National Eye Institute (NEI)
Frequently Asked Questions
Who can join the NCT02771236 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 120 Years, studying Inherited Eye Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02771236 currently recruiting?
Yes, NCT02771236 is actively recruiting participants. Contact the research team at f3h@helix.nih.gov for enrollment information.
Where is the NCT02771236 trial being conducted?
This trial is being conducted at La Jolla, United States, Bethesda, United States, Durham, United States, Guangzhou, China and 6 additional locations.
Who is sponsoring the NCT02771236 clinical trial?
NCT02771236 is sponsored by National Eye Institute (NEI). The principal investigator is James F Hejtmancik, M.D. at National Eye Institute (NEI). The trial plans to enroll 5,800 participants.